Amylyx Pharmaceuticals, Inc. logo AMLX - Amylyx Pharmaceuticals, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 10
HOLD 1
SELL 0
STRONG
SELL 0
| PRICE TARGET: $31.50 DETAILS
HIGH: $40.00
LOW: $24.00
MEDIAN: $31.00
CONSENSUS: $31.50
DOWNSIDE: 10.28%

Stock News

Amylyx Pharmaceuticals: Avexitide Defines The Endocrine Rebuild

Amylyx Pharmaceuticals: Avexitide Defines The Endocrine Rebuild

Amylyx Pharmaceuticals (AMLX) is transitioning from its ALS legacy to a late-stage endocrine company, with avexitide as its lead asset. AMLX's $250.8M cash runway extends into 2028, supporting LUCIDITY Phase 3 readout, regulatory submission, and potential 2027 launch without near-term financing risk. LUCIDITY's pivotal trial targets post-bariatric hypoglycemia, a large orphan market with no approved therapies; topline results expected late August or early September 2026.

Aug 07, 2026 07:28 AM • seekingalpha.com
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Amylyx Pharmaceuticals, Inc. – AMLX

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Amylyx Pharmaceuticals, Inc. – AMLX

BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed class action settlement that would benefit purchasers of publicly traded securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX): SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION To: All those who purchased or otherwise acquired Amylyx Pharmaceuticals, Inc. (“Amylyx”) securities between November 11, 2022, and November 8, 2023, inclusive (the “Class Period”), and who were allegedly damaged thereby (the “Settlement Class”). YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the District of Massachusetts, that Plaintiff Oliver Shih, on behalf of himself and all members of the proposed Settlement Class, and Amylyx, Joshua B.

Jun 08, 2026 04:00 AM • globenewswire.com (Hide legal announcements)
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Week 24 and Week 48 results from the Phase 2 open-label HELIOS clinical trial of AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol, in adults living with Wolfram syndrome have been published in The Journal of Clinical Investigation, a peer-reviewed medical journal. The publication reports Week 24 and Week 48 results from the Phase 2 ope.

May 15, 2026 08:11 AM • businesswire.com
Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the launch of a U.S. Expanded Access Program (EAP) for up to 250 adults with post-bariatric hypoglycemia (PBH) to provide treatment access to avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. The EAP allows U.S. physicians to request avexitide for adults with PBH following Roux-en-Y gastric bypass (RYGB) surgery who have a se.

May 05, 2026 03:00 AM • businesswire.com

Price Targets